Wed.Jan 03, 2024

article thumbnail

JPM24, Day 2: BioNTech warns of COVID vaccine sales decline; Alnylam looks to become 'top-tier' biopharma player

Fierce Pharma

As the J.P. | As the J.P. Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024.

Biopharma 318
article thumbnail

Goldman Sachs Closes $650M Fund to Invest in ‘Golden Era’ of Biotech Innovation

MedCity News

Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.

Medicine 121
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

With trial win for oral thalassemia drug, Agios charts broader path than gene therapy rivals

Fierce Pharma

Gene therapies have been approved for certain patients with beta thalassemia. After a successful phase 3 readout, Agios hopes it can reach a unique subgroup and eventually all patients. | Gene therapies have been approved for certain patients with beta thalassemia. After a successful phase 3 readout, Agios hopes it can reach a unique subgroup and eventually all patients.

Patients 301
article thumbnail

Aetna Better Health of Kentucky, Av?sis and MapHabit Launch Pilot Program for Vulnerable Patients

MedCity News

Aetna Better Health of Kentucky, Avēsis and MapHabit have teamed up to support 200 Kentucky children with autism or intellectual disabilities. The pilot program will help the patients with activities of daily living, such as oral hygiene.

Patients 119
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

JPM24, Day 3: Alkermes enters new phase after busy year

Fierce Pharma

As the J.P. Morgan Healthcare Conference moves into its third day, we're covering the latest developments here. | On Wednesday at the the J.P. Morgan Healthcare Conference, attendees will get a chance to hear from AbbVie, Amarin and several other pharmaceutical companies.

article thumbnail

MHRA’s post-Brexit mutual recognition framework goes live

pharmaphorum

The UK medicines regulator has launched its mutual recognition framework for authorising medicines in a move that it says will help to bring new drugs to patients in the UK more quickly.

Medicine 117

More Trending

article thumbnail

BJC-St. Luke’s Merger Will Be ‘the First of Many’ M&A Deals in the Hospital Sector This Year

MedCity News

On New Year’s Day, two Missouri health systems — St. Louis-based BJC HealthCare and Kansas City-based St. Luke’s Health System — officially completed their merger. The combined health system comprises 28 hospitals and hundreds of clinics serving 6 million people, and it is expected to generate $10 billion in annual revenue.

article thumbnail

JPM24, Day 1: Moderna touts $6.7B in '23 sales; Bluebird has cash on hand to last until early 2025

Fierce Pharma

As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. | As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. Plus, Moderna, bluebird and other companies updated investors on their businesses heading into 2024.

article thumbnail

MHRA authorisation is first endocrine therapy innovation in decades

European Pharmaceutical Review

Korserdu ® (elacestrant) is the first treatment indicated for ER+, HER2- advanced or metastatic breast cancer tumours with ESR1 mutations. The endocrine therapy has been granted a marketing authorisation by the UK Medicines & Healthcare products Regulatory Agency (MHRA). This represents the first endocrine therapy innovation in nearly 20 years. The small molecule treatment is authorised for postmenopausal women, and men, with oestrogen receptor (ER)-positive, HER2-negative, locally advanced

Medicine 105
article thumbnail

GSK amends commercial deal with Scynexis as antifungal recall drags into 2024

Fierce Pharma

When GSK laid out $90 million upfront to acquire rights to Scynexis’ antifungal Brexafemme last spring, the British pharma threw a lifeline to a company whose blockbuster launch ambitions had hit t | GSK has downgraded a licensing deal for Scynexis' antifungal ibrexafungerp following an ongoing recall of the drug's approved form, Brexafemme.

Pharma 233
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Outsourcing regulatory activities in pharma

European Pharmaceutical Review

Outsourcing has become a necessity for many pharmaceutical companies; even the outsourcing of regulatory functions has grown over the past several years and is expected to increase steadily in future. The pharmaceutical regulatory affairs outsourcing market is thus projected to rise from $7 billion in 2022 to $15 billion in 2032, 1 driven by the growing number of clinical trial applications (see Figure 1 ) 2 and product registrations.

Pharma 105
article thumbnail

Nexletol partners Esperion and Daiichi Sankyo patch up milestone dispute with $125M settlement

Fierce Pharma

After a dispute over milestone payments derailed a 2019 heart med collaboration, Daiichi Sankyo and Esperion Therapeutics have mended fences with a $125 million settlement. | The agreement amends terms of the companies' 2019 partnership on heart med Nexletol and dismisses Esperion's lawsuit over milestone payments ahead of a potential European label expansion.

167
167
article thumbnail

Alleviating Patient Burden in Clinical Trials: Modeling a Consumer-Grade Experience

MedCity News

By leveraging analytics to optimize the patient experience in clinical trials, patient attrition will decrease, improving clinical outcomes and research goals.

Patients 116
article thumbnail

Regulatory tracker: Menarini's Korserdu becomes UK's first new endocrine cancer fighter in decades

Fierce Pharma

Welcome to 2024's regulatory tracker for Fierce Pharma. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.

Pharma 130
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

CardioMech Snags $13M For Its Mitral Valve Repair Tech

MedCity News

Medical device startup CardioMech raised $13 million to advance the development and validation of its flagship device, which is designed to treat degenerative mitral valve regurgitation. The catheter-based device seeks to offer an uncomplicated, direct procedure for patients eligible for open-heart surgery as well as those considered eligible for the surgery.

Medical 110
article thumbnail

Expert analysis: the latest in HIV research and clinical trials 

Pharmaceutical Technology

A new report from Novotech delves into the multifaceted landscape of HIV, focusing on its impact, treatment, and global initiatives.

118
118
article thumbnail

From Last Resort to Mainstay: The Evolution of ECMO in Critical Care

MedCity News

The evolution of ECMO from a last-resort intervention to a mainstay of modern critical care is a testament to the relentless pursuit of better patient outcomes in the field of medicine. Unfortunately, despite the immense life-saving capability of this therapy, it remains vastly underutilized.

Medicine 108
article thumbnail

Boehringer Ingelheim agrees $2bn siRNA therapeutic collaboration

European Pharmaceutical Review

Boehringer Ingelheim has agreed to collaborate with Suzhou Ribo Life Science Co and Ribocure Pharmaceuticals AB (Ribo), to develop new RNAi therapeutics for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The deal exceeds a value of $2 billion and will utilise Ribo’s expertise in small interfering RNA (siRNA) treatments.

CRM 98
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

UK should remove blocks on phage research as AMR fears rise

pharmaphorum

UK report calls for the mothballed Rosalind Franklin Lab to be repurposed as a manufacturing unit to support clinical trials of bacteriophages as new antimicrobial agents

article thumbnail

Developing micro QC for ATMPs

European Pharmaceutical Review

What are the top trends relating to sterility testing of ATMPs? For me, one of the most promising developments involves the use of the next-generation sequencing-based sterility test (NGSST), which uses whole genome amplification and sequencing followed by microorganism identification with 48 hours. 1 This method removes the requirements for a culture period and has a higher accuracy than other rapid testing methods such as ATP bioluminescence.

article thumbnail

Boehringer reinforces interest in NASH with new $2bn deal  

Pharmaceutical Technology

This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.

98
article thumbnail

AnX Robotica receives FDA clearance for small bowel capsule endoscopy technology

PharmaTimes

NaviCam ProScan is the first AI-assisted reading tool for gastrointestinal bleeding

FDA 106
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Novartis allies with Voyager to develop gene therapies in $1.3bn deal

Pharmaceutical Technology

Novartis will pay Voyager $100m upfront and up to $1.2bn in milestone-based payments and royalties on net sales.

Sales 98
article thumbnail

Novo Nordisk to open new AI hub in UK for drug discovery

PharmaTimes

The new hub will be located in the King’s Cross Knowledge Quarter, London

103
103
article thumbnail

Inside the world of priority review vouchers where ‘time is money’ – Part I

Pharmaceutical Technology

The first of a two-part series on therapies that receive an FDA priority review designation dives into how these vouchers incentivise innovation for low-commercial value-diseases.

FDA 59
article thumbnail

The Weekly Wins of a Sales Superstar

Contrarian Sales Techniques

Navigating through a week in the sales world is like embarking on a mini-adventure, each day bringing its own set of challenges and triumphs. Let's break down the weekly routine of a sales superstar into beginning, middle, and end segments. This isn't just about getting through the week. It's about maximizing each day to its fullest potential. So, let's turn the pages of this weekly planner together.

Sales 59
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Invivyd Seeks EUA for Monoclonal Antibody Designed to Prevent COVID-19 in Immunocompromised Individuals

PharmExec

VYD222 is a broadly neutralizing, half-life extended monoclonal antibody developed specifically to prevent COVID-19 in immunocompromised adults and adolescents.

59
article thumbnail

How to Get Into Medical Sales: A Comprehensive Guide

Rep-Lite

Medical sales is the field of selling medical products and services to healthcare providers, such as hospitals, doctors, and clinics. Medical sales representatives typically work for pharmaceutical companies, medical device manufacturers, or healthcare service providers. Medical sales reps play a vital role in bringing new and innovative products and treatments to the market.

article thumbnail

The Midday Mastery of a Sales Superstar

Contrarian Sales Techniques

I'm back, and this time we're diving into the midday routine of a sales superstar. You know, that crucial part of the day when energy levels can either skyrocket or take a nosedive. It's the halftime of your workday, and how you spend it can really set the tone for the second act. So, grab your favorite midday snack, and let's unwrap the secrets to keeping that sales spark alive post-noon.

Sales 52
article thumbnail

Why We’re Salesforce Managed Services Expert Navigators

Penrod

The Heart of Salesforce Managed Services Since our founding in 2011, we’ve met and exceeded the standards for world-class Salesforce support by setting our sights on enhancing efficiency for our clients. Our services model revolves around focusing only on the healthcare industry. Penrod is proud to announce that our recent Managed Services Expert Navigator status has positioned us as one of the top three solution integrators for Salesforce services in the Healthcare and Life Sciences indus

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A